DE:OM3E ETF Price & Analysis
OM3E ETF Chart & Stats
€7.13
--
Market closed
€7.13
--
Day’s Range― - ―
52-Week Range€4.79 - €7.44
Previous Close€7.14
VolumeN/A
Average Volume (3M)N/A
AUM54.23M
NAV8.10
Expense Ratio0.35%
Holdings Count260
Beta0.52
Inception DateMar 06, 2018
Next Dividend Ex-DateN/A
Dividend Yield
(0.37%)Shares OutstandingN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
AlphaN/A
ETF Overview
iShares NASDAQ US Biotechnology UCITS ETF
The iShares NASDAQ US Biotechnology UCITS ETF, trading under the ticker DE:OM3E, is a powerful investment vehicle designed to capture the dynamic growth and innovation within the biotechnology sector of the healthcare industry. This exchange-traded fund (ETF) offers investors a targeted exposure to the cutting-edge advancements and potential breakthroughs in biotechnology, an area renowned for its rapid development and transformative impact on medical sciences and health solutions.
As a sector-focused ETF, DE:OM3E strategically invests in a diversified portfolio of biotechnology companies listed on the NASDAQ. These firms are at the forefront of developing novel therapies, pioneering genetic research, and revolutionizing patient care through groundbreaking biotechnological applications. By concentrating on this niche segment, the fund provides investors with a unique opportunity to participate in the potential upside of emerging biotech innovations, which are often characterized by high growth prospects and significant market disruptions.
The iShares NASDAQ US Biotechnology UCITS ETF is particularly appealing for those looking to diversify their investment portfolios with a thematic focus on the future of healthcare. It is tailored for investors who are keen on harnessing the potential of biopharmaceutical advancements, personalized medicine, and the burgeoning field of genomic research. With its specialized investment approach, DE:OM3E stands out as a compelling option for those aiming to invest in the next wave of healthcare evolution, while benefiting from the liquidity and flexibility inherent to ETFs.
iShares NASDAQ US Biotechnology UCITS ETF (OM3E) Fund Flow Chart
iShares NASDAQ US Biotechnology UCITS ETF (OM3E) 1 year Net Flows: €17M
OM3E ETF News
OM3E ETF FAQ
What was DE:OM3E’s price range in the past 12 months?
DE:OM3E lowest ETF price was €4.79 and its highest was €7.44 in the past 12 months.
What is the AUM of DE:OM3E?
As of Mar 20, 2026 The AUM of DE:OM3E is 54.23M.
Is DE:OM3E overvalued?
According to Wall Street analysts DE:OM3E’s price is currently Undervalued.
Does DE:OM3E pay dividends?
DE:OM3E does not currently pay dividends.
How many shares outstanding does DE:OM3E have?
Currently, no data Available
Which hedge fund is a major shareholder of DE:OM3E?
Currently, no hedge funds are holding shares in DE:OM3E
OM3E ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Gilead Sciences
9.71%
Vertex Pharmaceuticals Inc.
9.01%
Amgen Inc
8.80%
Regeneron Pharmaceuticals
6.11%
Alnylam Pharmaceuticals
3.31%
Insmed
2.42%
Biogen Inc.
2.13%
United Therapeutics Corp.
1.82%
Moderna
1.63%
Argenx
1.59%
Total46.51%
See All Holdings


